Colorado Bureau of Investigation

The committee meeting covered administrative items, including meeting recordings, open records act compliance, and member updates. Key discussion topics included general updates from the CBI, a report from the Trace Chemistry Unit Subcommittee, and a comprehensive budget overview. The meeting also addressed the formation of a new subcommittee focused on transparency, phase two planning and priorities, stakeholder engagement updates, and concluded with a public comment session.

The hearing was called to order to discuss proposed changes to the Colorado Automobile Theft Prevention Authority (CATPA) rules. The changes arise from an internal review, comments from the CATPA board, and recent legislation. The goal is to align with statutes, enhance clarity, expand the grant program to support victims of automobile theft, and improve technology. The exhibits concerning this rule are available online through the Colorado Department of Public Safety website.

The Board of Pharmacy convened to address various administrative matters, including a reminder for board members to complete cybersecurity and ethics training. They nominated Kristen Wolf for President and Ryan Leyland as Vice President. The board discussed Eli Lilly and Novo Nordisk requests, along with a stakeholder compounding question, delegating authority to staff to handle similar cases. A presentation on pain management was declined. The board addressed tabled items and licensing, including application reviews and complaint responses, often referring cases to executive session for confidentiality and potential disciplinary action. The meeting also covered ESP counteroffers and an Attorney General report, with board members attesting to the confidentiality of board matters.

The Board of Pharmacy convened to discuss several key items, including the revision of Policy 10-10 for PDMP Registration and Policy 30-19 for Ownership Changes. Rulemaking was initiated for Rule 3.00.80 regarding the implementation of SB 25-289, Rule 5.01.50 concerning the implementation of HB25-1222, Rule 8.00.20 regarding advertising, Rule 11.04.10 concerning the filing of prescription and chart orders, Rule 15.01.14(b) concerning the Ownership Change Timeline, and Rule 32.00.00 concerning Balance Billing. A request for Countertop Inches Space Consideration was denied. The board addressed a request to approve a Prescription Drug Label Accessibility exemption, ultimately deciding to deny the request, as well as a Board Vision Labeling Request. The board also reviewed Peer Assistance Service Reports. Numerous complaints and responses were discussed, with several cases being referred to executive session for further consideration, potential disciplinary action, or referral to other agencies such as the U.S. Food and Drug Administration or the State of Colorado Medical Board. Additionally, several cases were dismissed as being without merit, and some were tabled for more information. The board also discussed the Colorado PDMD Push Notice Threshold.

The Interfacility Transport Task Force meeting included discussions on the plan for monthly meetings, focusing on goal setting and information gathering. The task force reviewed existing knowledge of interfacility transfers and data from recent research, highlighting a 25% increase in IFTs over five years and increased 'time on task'. Discussions covered issues related to interfacility transfers, the differences between rural and urban settings, and the use of flight teams. Priorities were identified as equity and availability of access to out-of-hospital care, safety of providers and patients, and education and communication. The statutory authority and limitations around rule-making were discussed, with a focus on best practices and guidelines. The task force also discussed resource allocation, safety in transport, health system capabilities, and communication challenges. Goal setting included safety, resource allocation, funding, and education.